APA (7th ed.) Citation

JF, C., LF, X., R, Z., ZH, Z., YX, L., & XY, M. (2017). Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants. Acta haematologica, 137(4), 207. https://doi.org/10.1159/000471839

Chicago Style (17th ed.) Citation

JF, Chen, Xiao LF, Zhang R, Zeng ZH, Li YX, and Meng XY. "Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants." Acta Haematologica 137, no. 4 (2017): 207. https://doi.org/10.1159/000471839.

MLA (9th ed.) Citation

JF, Chen, et al. "Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants." Acta Haematologica, vol. 137, no. 4, 2017, p. 207, https://doi.org/10.1159/000471839.